Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

NCT04567420 is registered in ClinicalTrials.gov with Criterium, Inc. as lead sponsor.

NCT NCT04567420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04567420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Lead sponsor
Criterium, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 9, 2021
Completion date
December 31, 2028
Enrollment
70 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer